

PRESS RELEASE

innate pharma

INNATE PHARMA SA ANNOUNCES THE FULL EXERCISE OF THE GREENSHOE IN THE CONTEXT OF ITS IPO ON EUROLIST BY EURONEXT PARIS

Marseilles, November 27, 2006

Innate Pharma SA, a biopharmaceutical company specialising in immunology and developing first-in-class* drugs targeting the innate immune system, announces the full exercise of the over-allotment option (or "greenshoe") in the context of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris.

Bryan Garnier & Co. and Société Générale Corporate & Investment Banking, Joint Lead Managers and Joint Bookrunners of the offering, have notified to Innate Pharma that they were exercising the greenshoe in full, moving Innate Pharma's IPO gross proceeds from 29.9 million Euros to 33.7 million Euros, before deduction of banking fees.

Moreover, the Joint Lead Managers and Joint Bookrunners have indicated that they have not done any stabilisation operation on the Innate Pharma stock since the effective initial listing.

The exercise of the greenshoe will create 831,325 new shares. Total shares outstanding after the exercise of the greenshoe will amount to 24,748,684 shares.


Innate Pharma's free float will be around 27% of the outstanding capital.

About Innate Pharma

Founded in 1999, Innate Pharma S.A. is a biopharmaceutical company which develops first-in-class* drugs (currently in clinical trials) for targeting innate immunity. The pioneering work of Innate Pharma's scientific founders and research groups has generated three product platforms – each of which has been directly or indirectly validated in clinical oncology settings. In view of their mechanisms of action, Innate Pharma's drug candidates also have strong development potential in fields outside oncology, particularly in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials. Thanks to its strong scientific positioning in innate immunity pharmacology, its robust intellectual property portfolio and its R&D know-how, Innate Pharma intends to become a leading player in the rapidly growing immunotherapy market. Before its IPO, the company had already raised approximately 50 million euros in three rounds of VC financing (in 2000, 2002 and 2004), along with a reserved capital increase for its strategic partner, Novo Nordisk A/S, in 2006. In addition to Novo Nordisk A/S, historical investors in Innate Pharma are benchmark biotechnology players and include Sofinnova Partners (France), Alta Partners (USA), GIMV (Belgium), Axa Private Equity (France), Auriga Partners (France), INSERM Transfert (France), Gilde Healthcare (the Netherlands), Pechel Industries (France), Innoveris (France), NIF SMBC (Japan) and Quilvest Capital (France). Based in Marseilles, France, Innate Pharma's R&D immunotherapy activities are ISO 9001:2000 certified. As of August 31st, 2006,

* with new mechanisms of action.

**Not for direct or indirect circulation in the United States,
Canada, Australia or Japan**



PRESS RELEASE

innate pharma

Innate Pharma had 66 employees, including 16 with doctorates in science, medicine or pharmacy.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information:

ISIN code FR0010331421

Ticker code IPH

Disclaimer

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

Shares in Innate Pharma may not be sold in the United States of America (as defined under Regulation S of the U.S. Securities Act of 1933, as amended) absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. There will be no registration of all or part of the offering referred to in this press release in the United States nor any public offering of Innate Pharma in the United States.

This press release may not be distributed, either directly or indirectly, in the United States and does not constitute an offer to sell securities in the United States.

This press release does not contain or constitute an invitation or inducement to invest in any debt or equity securities issued by Innate Pharma (any such securities being referred to as "Innate Pharma Securities"). This press release is directed only at persons (1) who are outside the United Kingdom; (2) who have professional experience in matters related to investments; (3) who fall within Article 49(2)(a) to (d) (High net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (4) to whom such invitations and inducements to engage in investment activity within the meaning of section 21 of the Financial Services and Market Act 2000 in connection with the issue or sale of Innate Pharma Securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted or relied upon by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, other than France (each, a "Relevant Member State"), this press release does not contain or constitute an offer of shares to the public in any such Relevant Member State in any manner requiring the publication of a prospectus. Shares may only be offered in any Relevant Member State, other than France, in a manner that does not require the publication of a prospectus, as provided in article 3.2 of the Prospectus Directive.

For any additional information, please contact:

Innate Pharma

Stéphane Boissel, CFO

Tel. : +33 (0)4 96 19 05 58

stephane.boissel@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol

Tel. : +33 (0)6 64 18 99 59

caroline.carmagnol@wanadoo.fr

**Not for direct or indirect circulation in the United States,
Canada, Australia or Japan**